Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 6/20 | 0.51 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545475 | 0.90 | RPS6KA3 (0.48) | RPS6KA3SLC22A12NR1H2 | |
| SCHEMBL6739531 | 0.88 | RPS6KA3 (0.45) | RPS6KA3DHODHSLC22A12DYRK1ANR1H2 | |
| SCHEMBL6735871 | 0.88 | RPS6KA3 (0.55) | RPS6KA3DHODHSLC22A12DYRK1ANR1H2 | |
| SCHEMBL7182901 | 0.84 | ALOX5AP (0.47) | RPS6KA3SLC22A12NR1H2NR1H3 | |
| SCHEMBL7545909 | 0.83 | SLC22A12 (0.57) | RPS6KA3SLC22A12NR1H2NR1H3 | |
| SCHEMBL7047515 | 0.83 | PTGS2 (0.42) | RPS6KA3SLC22A12NR1H2NR1H3 | |
| SCHEMBL7537413 | 0.83 | PTGS2 (0.42) | RPS6KA3SLC22A12NR1H2NR1H3 | |
| SCHEMBL7045230 | 0.83 | RPS6KA3 (0.57) | RPS6KA3SLC22A12 | |
| SCHEMBL6725499 | 0.82 | PTGS2 (0.46) | DHODHNR1H2NR1H3PIM1PIM2 | |
| SCHEMBL7541582 | 0.82 | DHODH (0.43) | DHODHDYRK1ANR1H2NR1H3CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | RPS6KA3 1119/4885DHODH 2109/4885SLC22A12 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.